The Experts below are selected from a list of 21594 Experts worldwide ranked by ideXlab platform

Frank Ulrich - One of the best experts on this subject based on the ideXlab platform.

  • mr guided laser induced interstitial thermotherapy of recurrent Glioblastoma Multiforme preliminary results in 16 patients
    European Journal of Radiology, 2006
    Co-Authors: Hansjoachim Schwarzmaier, Frank Eickmeyer, Wernholt Von Tempelhoff, Volkhard Ulrich Fiedler, Hendrik Niehoff, Slif Dagobert Ulrich, Qin Yang, Frank Ulrich
    Abstract:

    We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent Glioblastoma Multiforme. The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation. All patients received standard chemotherapy (temozolomide). The median overall survival time after the first relapse was 9.4 months, corresponding to a median overall survival time after laser irradiation of 6.9 months. During the study, however, the median survival after laser coagulation increased to 11.2 months. This survival time is substantially longer than those reported for the natural history (<5 months) or after chemotherapy (temozolomide: 5.4-7.1 months). We conclude that cytoreduction by laser irradiation might be a promising option for patients suffering from recurrent Glioblastoma Multiforme. In addition, the data indicate the presence of a substantial learning curve. Future work should optimize the therapeutic regimen and evaluate this treatment approach in controlled clinical trials.

  • mr guided laser induced interstitial thermotherapy of recurrent Glioblastoma Multiforme preliminary results in 16 patients
    European Journal of Radiology, 2006
    Co-Authors: Hansjoachim Schwarzmaier, Frank Eickmeyer, Hendrik Niehoff, Slif Dagobert Ulrich, Qin Yang, Wernholt Von Tempelhoff, V Fiedler, Frank Ulrich
    Abstract:

    Abstract We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent Glioblastoma Multiforme. The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation. All patients received standard chemotherapy (temozolomide). The median overall survival time after the first relapse was 9.4 months, corresponding to a median overall survival time after laser irradiation of 6.9 months. During the study, however, the median survival after laser coagulation increased to 11.2 months. This survival time is substantially longer than those reported for the natural history (

Hansjoachim Schwarzmaier - One of the best experts on this subject based on the ideXlab platform.

  • mr guided laser induced interstitial thermotherapy of recurrent Glioblastoma Multiforme preliminary results in 16 patients
    European Journal of Radiology, 2006
    Co-Authors: Hansjoachim Schwarzmaier, Frank Eickmeyer, Wernholt Von Tempelhoff, Volkhard Ulrich Fiedler, Hendrik Niehoff, Slif Dagobert Ulrich, Qin Yang, Frank Ulrich
    Abstract:

    We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent Glioblastoma Multiforme. The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation. All patients received standard chemotherapy (temozolomide). The median overall survival time after the first relapse was 9.4 months, corresponding to a median overall survival time after laser irradiation of 6.9 months. During the study, however, the median survival after laser coagulation increased to 11.2 months. This survival time is substantially longer than those reported for the natural history (<5 months) or after chemotherapy (temozolomide: 5.4-7.1 months). We conclude that cytoreduction by laser irradiation might be a promising option for patients suffering from recurrent Glioblastoma Multiforme. In addition, the data indicate the presence of a substantial learning curve. Future work should optimize the therapeutic regimen and evaluate this treatment approach in controlled clinical trials.

  • mr guided laser induced interstitial thermotherapy of recurrent Glioblastoma Multiforme preliminary results in 16 patients
    European Journal of Radiology, 2006
    Co-Authors: Hansjoachim Schwarzmaier, Frank Eickmeyer, Hendrik Niehoff, Slif Dagobert Ulrich, Qin Yang, Wernholt Von Tempelhoff, V Fiedler, Frank Ulrich
    Abstract:

    Abstract We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent Glioblastoma Multiforme. The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation. All patients received standard chemotherapy (temozolomide). The median overall survival time after the first relapse was 9.4 months, corresponding to a median overall survival time after laser irradiation of 6.9 months. During the study, however, the median survival after laser coagulation increased to 11.2 months. This survival time is substantially longer than those reported for the natural history (

Hendrik Niehoff - One of the best experts on this subject based on the ideXlab platform.

  • mr guided laser induced interstitial thermotherapy of recurrent Glioblastoma Multiforme preliminary results in 16 patients
    European Journal of Radiology, 2006
    Co-Authors: Hansjoachim Schwarzmaier, Frank Eickmeyer, Wernholt Von Tempelhoff, Volkhard Ulrich Fiedler, Hendrik Niehoff, Slif Dagobert Ulrich, Qin Yang, Frank Ulrich
    Abstract:

    We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent Glioblastoma Multiforme. The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation. All patients received standard chemotherapy (temozolomide). The median overall survival time after the first relapse was 9.4 months, corresponding to a median overall survival time after laser irradiation of 6.9 months. During the study, however, the median survival after laser coagulation increased to 11.2 months. This survival time is substantially longer than those reported for the natural history (<5 months) or after chemotherapy (temozolomide: 5.4-7.1 months). We conclude that cytoreduction by laser irradiation might be a promising option for patients suffering from recurrent Glioblastoma Multiforme. In addition, the data indicate the presence of a substantial learning curve. Future work should optimize the therapeutic regimen and evaluate this treatment approach in controlled clinical trials.

  • mr guided laser induced interstitial thermotherapy of recurrent Glioblastoma Multiforme preliminary results in 16 patients
    European Journal of Radiology, 2006
    Co-Authors: Hansjoachim Schwarzmaier, Frank Eickmeyer, Hendrik Niehoff, Slif Dagobert Ulrich, Qin Yang, Wernholt Von Tempelhoff, V Fiedler, Frank Ulrich
    Abstract:

    Abstract We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent Glioblastoma Multiforme. The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation. All patients received standard chemotherapy (temozolomide). The median overall survival time after the first relapse was 9.4 months, corresponding to a median overall survival time after laser irradiation of 6.9 months. During the study, however, the median survival after laser coagulation increased to 11.2 months. This survival time is substantially longer than those reported for the natural history (

Frank Eickmeyer - One of the best experts on this subject based on the ideXlab platform.

  • mr guided laser induced interstitial thermotherapy of recurrent Glioblastoma Multiforme preliminary results in 16 patients
    European Journal of Radiology, 2006
    Co-Authors: Hansjoachim Schwarzmaier, Frank Eickmeyer, Wernholt Von Tempelhoff, Volkhard Ulrich Fiedler, Hendrik Niehoff, Slif Dagobert Ulrich, Qin Yang, Frank Ulrich
    Abstract:

    We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent Glioblastoma Multiforme. The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation. All patients received standard chemotherapy (temozolomide). The median overall survival time after the first relapse was 9.4 months, corresponding to a median overall survival time after laser irradiation of 6.9 months. During the study, however, the median survival after laser coagulation increased to 11.2 months. This survival time is substantially longer than those reported for the natural history (<5 months) or after chemotherapy (temozolomide: 5.4-7.1 months). We conclude that cytoreduction by laser irradiation might be a promising option for patients suffering from recurrent Glioblastoma Multiforme. In addition, the data indicate the presence of a substantial learning curve. Future work should optimize the therapeutic regimen and evaluate this treatment approach in controlled clinical trials.

  • mr guided laser induced interstitial thermotherapy of recurrent Glioblastoma Multiforme preliminary results in 16 patients
    European Journal of Radiology, 2006
    Co-Authors: Hansjoachim Schwarzmaier, Frank Eickmeyer, Hendrik Niehoff, Slif Dagobert Ulrich, Qin Yang, Wernholt Von Tempelhoff, V Fiedler, Frank Ulrich
    Abstract:

    Abstract We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent Glioblastoma Multiforme. The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation. All patients received standard chemotherapy (temozolomide). The median overall survival time after the first relapse was 9.4 months, corresponding to a median overall survival time after laser irradiation of 6.9 months. During the study, however, the median survival after laser coagulation increased to 11.2 months. This survival time is substantially longer than those reported for the natural history (

Slif Dagobert Ulrich - One of the best experts on this subject based on the ideXlab platform.

  • mr guided laser induced interstitial thermotherapy of recurrent Glioblastoma Multiforme preliminary results in 16 patients
    European Journal of Radiology, 2006
    Co-Authors: Hansjoachim Schwarzmaier, Frank Eickmeyer, Wernholt Von Tempelhoff, Volkhard Ulrich Fiedler, Hendrik Niehoff, Slif Dagobert Ulrich, Qin Yang, Frank Ulrich
    Abstract:

    We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent Glioblastoma Multiforme. The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation. All patients received standard chemotherapy (temozolomide). The median overall survival time after the first relapse was 9.4 months, corresponding to a median overall survival time after laser irradiation of 6.9 months. During the study, however, the median survival after laser coagulation increased to 11.2 months. This survival time is substantially longer than those reported for the natural history (<5 months) or after chemotherapy (temozolomide: 5.4-7.1 months). We conclude that cytoreduction by laser irradiation might be a promising option for patients suffering from recurrent Glioblastoma Multiforme. In addition, the data indicate the presence of a substantial learning curve. Future work should optimize the therapeutic regimen and evaluate this treatment approach in controlled clinical trials.

  • mr guided laser induced interstitial thermotherapy of recurrent Glioblastoma Multiforme preliminary results in 16 patients
    European Journal of Radiology, 2006
    Co-Authors: Hansjoachim Schwarzmaier, Frank Eickmeyer, Hendrik Niehoff, Slif Dagobert Ulrich, Qin Yang, Wernholt Von Tempelhoff, V Fiedler, Frank Ulrich
    Abstract:

    Abstract We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent Glioblastoma Multiforme. The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation. All patients received standard chemotherapy (temozolomide). The median overall survival time after the first relapse was 9.4 months, corresponding to a median overall survival time after laser irradiation of 6.9 months. During the study, however, the median survival after laser coagulation increased to 11.2 months. This survival time is substantially longer than those reported for the natural history (